Drug Approval | June 27, 2025
SMS Pharmaceuticals completes USFDA inspection at Central Laboratory Analytical Services
The inspection concluded with zero Form 483 observations
The inspection concluded with zero Form 483 observations
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Subscribe To Our Newsletter & Stay Updated
